• Complex
  • Title
  • Keyword
  • Abstract
  • Scholars
  • Journal
  • ISSN
  • Conference
成果搜索

author:

Chen, L. (Chen, L..) [1] | Li, X. (Li, X..) [2] | Cheng, M. (Cheng, M..) [3] | Wang, S. (Wang, S..) [4] | Zheng, Q. (Zheng, Q..) [5] | Liu, Q. (Liu, Q..) [6]

Indexed by:

Scopus

Abstract:

The occurrence of multidrug resistance (MDR) is highly associated with the overexpression of ATP-binding cassette (ABC) transporters, among which, P-glycoprotein (P-gp) plays one of the most important roles. Iso-pencillixanthone A (iso-PXA) is a compound isolated from the marine-derived fungus Penicillium oxalicum. No studies on the anti-tumor effect of this compound have been reported, except for a few focusing on its bactericidal properties. In this study, we found iso-PXA could stimulate P-gp ATPase activity and attenuate P-gp expression to increase the intracellular drug concentration in the cervical vincristine (VCR)-resistant cell line HeLa/VCR. Then, it increased ROS generation, depolarized MMP, promoted the release of cytochrome c from mitochondria, and further activated caspase-9, caspase-3 and PARP to induce cell apoptosis effectively through the intrinsic pathway. Caspase-8 medicated cleavage of Bid into the truncated form tBid partially initiated the mitochondrial apoptotic events. The elevation of the Bax/Bcl-2 ratio, the accumulation of FBW7 and the degradation of Mcl-1 accelerated the iso-PXA induced apoptotic process. The HeLa/VCR cell xenograft model again confirmed that iso-PXA had much better efficacy than vincristine in vivo. Taken together, these findings demonstrated that iso-PXA elicited remarkable anti-tumor and anti-MDR activity through inhibiting P-gp expression and function and re-activating the intrinsic apoptosis pathway in vitro and in vivo, suggesting it as a potential chemotherapeutic lead compound in the treatment of cervical MDR cancers. © The Royal Society of Chemistry.

Keyword:

Community:

  • [ 1 ] [Chen, L.]Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou, 350002, China
  • [ 2 ] [Li, X.]Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou, 350002, China
  • [ 3 ] [Cheng, M.]Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou, 350002, China
  • [ 4 ] [Wang, S.]Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou, 350002, China
  • [ 5 ] [Zheng, Q.]Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, 350014, China
  • [ 6 ] [Liu, Q.]Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, 350014, China

Reprint 's Address:

  • [Zheng, Q.]Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer HospitalChina

Show more details

Related Keywords:

Related Article:

Source :

RSC Advances

ISSN: 2046-2069

Year: 2018

Issue: 72

Volume: 8

Page: 41192-41206

3 . 0 4 9

JCR@2018

3 . 9 0 0

JCR@2023

ESI HC Threshold:209

JCR Journal Grade:2

CAS Journal Grade:3

Cited Count:

WoS CC Cited Count:

SCOPUS Cited Count: 10

ESI Highly Cited Papers on the List: 0 Unfold All

WanFang Cited Count:

Chinese Cited Count:

30 Days PV: 2

Affiliated Colleges:

Online/Total:106/10103698
Address:FZU Library(No.2 Xuyuan Road, Fuzhou, Fujian, PRC Post Code:350116) Contact Us:0591-22865326
Copyright:FZU Library Technical Support:Beijing Aegean Software Co., Ltd. 闽ICP备05005463号-1